Journal of Hepatology最新文献

{"title":"Corrigendum to: “A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease” [J Hepatol (2022) 765-767]","authors":"Wajahat Z. Mehal, Robert F. Schwabe","doi":"10.1016/j.jhep.2024.10.004","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.10.004","url":null,"abstract":"It has come to our attention that the following text should have been included in the ‘Financial support’ section of this article: “Dr. Mehal has an appointment at the West Haven VA Medical Center and this work was supported by a US Department of Veterans Office of Research & Development with grant BX003259-05A1”. We apologise for any inconvenience caused.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"4 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142684544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Letter to Editor: Communicating the complexity of the transplant benefit score","authors":"Elisa Allen, Rhiannon Taylor, Alex Gimson, Douglas Thorburn","doi":"10.1016/j.jhep.2024.11.026","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.026","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors’ contributions:</h2>EA, RT, AG and DT wrote and edited this response.</section></section><section><section><h2>Financial support statement:</h2>None declared.</section></section><section><section><h2>Declaration of Competing Interest:</h2>None declared.</section></section><section><section><h2>Acknowledgements:</h2>We thank Dr Varuna Aluvihare (Chair of the LAG &amp; Institute of Liver Studies, King’s College Hospital, London, UK) and Prof Derek Manas (OTDT Medical Director, NHS Blood and Transplant, Newcastle upon Tyne, UK) for their helpful comments on an earlier version of this response.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"255 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142690693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human albumin administration at the time of large volume paracentesis: a modified Delphi study","authors":"Yassin Magdy Ibrahim, Elliot Benjamin Tapper, Joost PH. Drenth, Marten Alexander Lantinga","doi":"10.1016/j.jhep.2024.11.027","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.027","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Author contributions</h2>ET, JD, ML contributed to concept and design. ML conducted the Delphi survey, ML performed analyses. All authors contributed to interpretation of results. All authors contributed to writing of the article.</section></section><section><section><h2>Financial support statement</h2>No funding was available for this study.</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors declare that they have no competing interests.</section></section><section><section><h2>Acknowledgements</h2>We would like to express our gratitude to the individual Delphi panel members:Sumeet Asrani (Baylor University Medical Center, Dallas, Texas, USA); Mauro Bernardi (Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy); Patrizia Burra (Gastroenterology and Multivisceral Transplant Unit, Department of Surgery, Oncology, and Gastroenterology, Padua University Hospital, Padua, Italy); Paolo Caraceni (Department of Medical and Surgical Sciences, Alma Mater Studiorum</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"1 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142690764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards more consistent models and consensual terminology in preclinical research for Steatotic Liver Disease","authors":"Abraham S. Meijnikman, Marcos F. Fondevila, Marco Arrese, Tatiana Kisseleva, Ramon Bataller, Bernd Schnabl","doi":"10.1016/j.jhep.2024.11.025","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.025","url":null,"abstract":"Steatotic liver disease (SLD) is one of the most prevalent liver conditions globally and a leading cause of liver transplantation, yet therapeutic advancements have not kept pace with its major impact on global morbidity and mortality. This underscores the critical importance of developing and refining relevant preclinical animal models. However, preclinical research has faced significant challenges, with concerns about the translational validity of animal models, as findings often fail to accurately reflect human disease. With the recent adoption of new nomenclature for SLD in humans, questions have arisen about how to integrate these changes into preclinical models. Here, we offer suggestions on how to improve preclinical models, including the incorporation of factors such as diet, alcohol, and other metabolic stressors, to better replicate the complexity of human disease. While implementing these improvements presents logistical challenges, doing so is essential to enhancing the translational relevance and reproducibility of animal studies, and advancing therapeutic discoveries. Furthermore, we address the persisting inconsistency in terminology used in animal studies and propose clinically meaningful terms that can be applied consistently to preclinical research.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"71 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142690698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PLEX for Acute Liver Failure in UK National Cohort: A situation perplexed!","authors":"Dhiraj Agrawal, Kishore Kumar Ariga, Guru N. Reddy","doi":"10.1016/j.jhep.2024.11.020","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.020","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Author’s contributions</h2>DA, Initial draft, revision, and editing, KA, Data acquisition and editing, GNR, Final approval</section></section><section><section><h2>Financial support and sponsorship</h2>None</section></section><section><section><h2>Declaration of Competing Interest</h2>Nothing to report</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"11 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142673289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma exchange for acute liver failure in a real-world cohort: what it was and should have never been.","authors":"David Toapanta, Natalia Jiménez-Esquivel, Enric Reverter","doi":"10.1016/j.jhep.2024.11.021","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.021","url":null,"abstract":"No Abstract","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"110 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142684589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: “Insights into Fracture Risk with Tenofovir and Entecavir: Evidence from Pharmacovigilance Data”","authors":"Jimmy Che-To Lai, Mary Yue Wang, Terry Cheuk-Fung Yip","doi":"10.1016/j.jhep.2024.11.019","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.019","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions:</h2>All authors were responsible for the study concept, data acquisition and analysis, the integrity of the data and the accuracy of the data analysis, the drafting, and the critical revision of the manuscript for important intellectual content, and approved the final version of the article. Terry Yip is the submission’s guarantor of the article.</section></section><section><section><h2>Financial support:</h2>None</section></section><section><section><h2>Declaration of Competing Interest:</h2>Jimmy Lai has served as a speaker for Gilead Sciences and an advisory board committee for Gilead Sciences and Boehringer Ingelheim.Terry Yip has served as an advisory committee member and a speaker for Gilead Sciences.Mary Wang declares that she has no competing interests.We extend our sincere gratitude to Ge <em>et al.</em> [1] for their valuable insights on our territory-wide cohort study, which involved patients identified from the Clinical Data Analysis and Reporting System (CDARS) of the Hospital</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"10 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142673345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: a systematic review and meta-analysis","authors":"Jimmy Che-To Lai, Grace Lai-Hung Wong, Yee-Kit Tse, Vicki Wing-Ki Hui, Mandy Sze-Man Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip","doi":"10.1016/j.jhep.2024.11.018","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.018","url":null,"abstract":"&lt;h3&gt;Background &amp; Aims&lt;/h3&gt;Current international guidelines recommend close monitoring and evaluation of patients with chronic hepatitis B (CHB) in the indeterminate phase, and treatment of patients at high risk of adverse outcomes. Clinical outcomes and the effect of antiviral therapy on the indeterminate phase remain unclear. We performed a systematic review and meta-analysis to study the incidence of adverse clinical outcomes including hepatocellular carcinoma (HCC), cirrhosis, and hepatic decompensation, and the effect of antiviral therapy, in the indeterminate phase.&lt;h3&gt;Methods&lt;/h3&gt;Two investigators independently searched Embase, MEDLINE, Web of Science and China National Knowledge Infrastructure from 1/1/2007 to 31/12/2023. Three investigators independently assessed study eligibility and quality. We included cohort studies and randomised controlled trials (RCTs) allowing calculation of the incidence rate of adverse clinical outcomes, and cross-sectional studies that reported the prevalence of moderate-to-severe inflammation and different degrees of fibrosis. Incidence rates and prevalence were pooled using generalised linear mixed-effects models and random-effects models, respectively.&lt;h3&gt;Results&lt;/h3&gt;One hundred and three studies (70 case-control studies [18,739 patients], 32 cohort studies [15,118 patients], 1 RCT [160 patients]) were included. The annual incidence rate of HCC in patients in the indeterminate phase was 0.32% (95% CI 0.21-0.48%, I&lt;sup&gt;2&lt;/sup&gt;=85.7%), and those of cirrhosis and hepatic decompensation were 0.67% (95% CI 0.30-1.49%, I&lt;sup&gt;2&lt;/sup&gt;=94.3%) and 0.34% (95% CI 0.17-0.69%, I&lt;sup&gt;2&lt;/sup&gt;=51.8%), respectively. The pooled prevalence of moderate-to-severe liver inflammation, significant fibrosis, advanced fibrosis, and cirrhosis was 40.7, 39.7%, 17.9%, and 7.2%, respectively. Use of antiviral therapy was associated with a lower risk of HCC in patients in the indeterminate phase (adjusted incidence rate ratio 0.38, 95% CI 0.18-0.79, p=0.009).&lt;h3&gt;Conclusions&lt;/h3&gt;Patients in the indeterminate phase are at risk of developing advanced liver disease and HCC. Although inherent heterogeneity across studies limited the evidence to support expanding treatment to all patients in the indeterminate phase, antiviral therapy may reduce the risk of HCC development in high-risk subgroups.&lt;h3&gt;IMPACT AND IMPLICATIONS&lt;/h3&gt;Current international guidelines recommend close monitoring and evaluation of patients with chronic hepatitis B (CHB) in the indeterminate phase, and not all of these patients are indicated for antiviral treatment. Based on the systematic review and meta-analysis with significant heterogeneity across studies, patients in the indeterminate phase are at risk of developing hepatocellular carcinoma (HCC), cirrhosis, and hepatic decompensation. Meta-regression findings on platelet count, positive HBeAg, and age highlighted the importance of liver fibrosis assessment, accurate phase classification, and timely detection of pha","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"46 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142684590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Fracture Risk with TDF in Elderly Hepatitis B Patients: A Korean Perspective","authors":"Yoon E. Shin, Jae Young Kim, Jeong Ju Yoo, Sang Gyune Kim, Young Seok Kim","doi":"10.1016/j.jhep.2024.11.022","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.022","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Data availability statement (delete if not applicable)</h2>Raw data were generated at Korean Health Insurance Review and Assessment Service (HIRA) database. Derived data supporting the findings of this study are available from the corresponding author Jeong Ju Yoo on request.</section></section><section><section><h2>Authors' contributions</h2>Conceptualization, Jeong-Ju Yoo; Methodology, Jae Young Kim; Formal analysis, Jae Young Kim; Investigation, Sang Gyune Kim and Young Seok Kim; Resources, Sang Gyune Kim and Young Seok Kim; Writing - Original Draft, Yoon E Shin and Jeong-Ju Yoo; Writing - Review &amp; Editing, all authors</section></section><section><section><h2>Financial support</h2>None</section></section><section><section><h2>Declaration of Competing Interest</h2>NonePlease refer to the accompanying ICMJE disclosure forms for further details.</section></section><section><section><h2>Acknowledgements</h2>This study was supported by the Soonchunhyang University Research Fund.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"254 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142684586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world clinical data-driven modelling on the initiation time of antiviral prophylaxis among pregnant women with chronic hepatitis B infection","authors":"Mingwang Shen, Shihao He, Naijuan Yao, Rui Li, Jing Wang, Wenting Zhong, Jinyan Wang, Huihui Wang, Li Xie, Guihua Zhuang, Lei Zhang, Tianyan Chen","doi":"10.1016/j.jhep.2024.11.017","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.017","url":null,"abstract":"&lt;h3&gt;Background &amp; Aims&lt;/h3&gt;The risk of mother-to-child transmission (MTCT) for pregnant women with chronic hepatitis B (CHB) infection still exists, especially for those with high HBV DNA level. The guidelines for initiating prophylaxis for pregnant women with CHB vary across countries. We aimed to explore the latest prophylaxis initiation time for these women.&lt;h3&gt;Methods&lt;/h3&gt;We collected the real-world clinical data of 328 pregnant women with CHB infection aged 20-49 treated by telbivudine (LdT) or tenofovir disoproxil fumarate (TDF) from July 2010 to December 2020 in China. A mathematical model was developed to describe the viral kinetics of HBV after prophylaxis. We calculated the time required to reduce viral load below the threshold value of 5.3 log&lt;sub&gt;10&lt;/sub&gt; IU/mL. We derived the prophylaxis initiation time by subtracting the required time to threshold from the childbirth gestational week.&lt;h3&gt;Results&lt;/h3&gt;The median time for 328 women to reduce HBV DNA levels below the threshold of 5.3 log&lt;sub&gt;10&lt;/sub&gt; IU/mL was 4.2 (range: 0.2-12.8) weeks, corresponding to prophylaxis initiation time of no later than 35.1 (25.2-41.4) weeks. Specifically, for women with viral loads &gt; 8.0 log&lt;sub&gt;10&lt;/sub&gt; IU/mL, prophylaxis should be initiated before 33.9 (25.2-39.5) weeks, and particularly before the lower bound of 25.2 weeks, to maximize clinical safety. For women with viral load &gt;7.0 to &lt;span&gt;&lt;span style=\"display: none;\"&gt;&lt;/span&gt;&lt;span data-mathml='&lt;math xmlns=\"http://www.w3.org/1998/Math/MathML\"&gt;&lt;mrow is=\"true\"&gt;&lt;mo linebreak=\"goodbreak\" linebreakstyle=\"after\" is=\"true\"&gt;&amp;#x2264;&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;' role=\"presentation\" style=\"position: relative;\" tabindex=\"0\"&gt;&lt;span aria-hidden=\"true\"&gt;[Math Processing Error]&lt;/span&gt;&lt;span role=\"presentation\"&gt;&lt;math xmlns=\"http://www.w3.org/1998/Math/MathML\"&gt;&lt;mrow is=\"true\"&gt;&lt;mo is=\"true\" linebreak=\"goodbreak\" linebreakstyle=\"after\"&gt;≤&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt;&lt;/span&gt;&lt;script type=\"math/mml\"&gt;&lt;math&gt;&lt;mrow is=\"true\"&gt;&lt;mo linebreak=\"goodbreak\" linebreakstyle=\"after\" is=\"true\"&gt;≤&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/script&gt;&lt;/span&gt; 8.0 log&lt;sub&gt;10&lt;/sub&gt; IU/mL, prophylaxis should be initiated before 35.5 (28.6-39.8) weeks, and for women with viral load &gt;5.3 to &lt;span&gt;&lt;span style=\"display: none;\"&gt;&lt;/span&gt;&lt;span data-mathml='&lt;math xmlns=\"http://www.w3.org/1998/Math/MathML\"&gt;&lt;mrow is=\"true\"&gt;&lt;mo linebreak=\"goodbreak\" linebreakstyle=\"after\" is=\"true\"&gt;&amp;#x2264;&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;' role=\"presentation\" style=\"position: relative;\" tabindex=\"0\"&gt;&lt;span aria-hidden=\"true\"&gt;[Math Processing Error]&lt;/span&gt;&lt;span role=\"presentation\"&gt;&lt;math xmlns=\"http://www.w3.org/1998/Math/MathML\"&gt;&lt;mrow is=\"true\"&gt;&lt;mo is=\"true\" linebreak=\"goodbreak\" linebreakstyle=\"after\"&gt;≤&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt;&lt;/span&gt;&lt;script type=\"math/mml\"&gt;&lt;math&gt;&lt;mrow is=\"true\"&gt;&lt;mo linebreak=\"goodbreak\" linebreakstyle=\"after\" is=\"true\"&gt;≤&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/script&gt;&lt;/span&gt; 7.0 log&lt;sub&gt;10&lt;/sub&gt; IU/mL, prophylaxis should be initiated befo","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"16 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142684588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}